1. Home
  2. CVKD vs GRNQ Comparison

CVKD vs GRNQ Comparison

Compare CVKD & GRNQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CVKD
  • GRNQ
  • Stock Information
  • Founded
  • CVKD 2022
  • GRNQ 2013
  • Country
  • CVKD United States
  • GRNQ Malaysia
  • Employees
  • CVKD N/A
  • GRNQ N/A
  • Industry
  • CVKD Medicinal Chemicals and Botanical Products
  • GRNQ EDP Services
  • Sector
  • CVKD Health Care
  • GRNQ Technology
  • Exchange
  • CVKD Nasdaq
  • GRNQ Nasdaq
  • Market Cap
  • CVKD 8.2M
  • GRNQ 7.8M
  • IPO Year
  • CVKD 2023
  • GRNQ 2018
  • Fundamental
  • Price
  • CVKD $0.43
  • GRNQ $1.08
  • Analyst Decision
  • CVKD Strong Buy
  • GRNQ
  • Analyst Count
  • CVKD 2
  • GRNQ 0
  • Target Price
  • CVKD $3.50
  • GRNQ N/A
  • AVG Volume (30 Days)
  • CVKD 71.6K
  • GRNQ 621.0K
  • Earning Date
  • CVKD 08-12-2024
  • GRNQ 08-09-2024
  • Dividend Yield
  • CVKD N/A
  • GRNQ N/A
  • EPS Growth
  • CVKD N/A
  • GRNQ N/A
  • EPS
  • CVKD N/A
  • GRNQ 0.09
  • Revenue
  • CVKD N/A
  • GRNQ $3,498,328.00
  • Revenue This Year
  • CVKD N/A
  • GRNQ N/A
  • Revenue Next Year
  • CVKD N/A
  • GRNQ N/A
  • P/E Ratio
  • CVKD N/A
  • GRNQ $11.89
  • Revenue Growth
  • CVKD N/A
  • GRNQ N/A
  • 52 Week Low
  • CVKD $0.36
  • GRNQ $0.72
  • 52 Week High
  • CVKD $2.17
  • GRNQ $1.88
  • Technical
  • Relative Strength Index (RSI)
  • CVKD 40.00
  • GRNQ 50.28
  • Support Level
  • CVKD $0.43
  • GRNQ $0.87
  • Resistance Level
  • CVKD $0.49
  • GRNQ $1.65
  • Average True Range (ATR)
  • CVKD 0.02
  • GRNQ 0.17
  • MACD
  • CVKD -0.00
  • GRNQ 0.03
  • Stochastic Oscillator
  • CVKD 0.17
  • GRNQ 26.51

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management, cross-border listing advisory services, and transaction services. It also operates a venture capital business. Its segments include Service business engaged in the provision of corporate advisory and business solution services; and Real estate business engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia.

Share on Social Networks: